[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-327154-105":3,"detail-sidebar-cat-0-en-105":73,"doc-detail-327154-en":122},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":66,"head_meta":68,"extra_data":70,"updated_unix":72},105,"en","advances-in-targeted-therapy-and-biomarker-research-in-thyroid-cancer","Advances in targeted therapy and biomarker research in thyroid cancer","","Targeted therapy and biomarker research are presented as major advances for thyroid cancer driven by the complexity of disease and the need for individualized treatment. Genetic alterations across thyroid cancer require further investigation to clarify molecular mechanisms and support clinically significant, customized therapeutic planning. Targeted therapies focus on defined molecular targets such as mutant BRAF or RET, potentially limiting damage to healthy tissues and reducing adverse effects. Biomarkers enable patient stratification by molecular profiles, supporting precision medicine and improving prognosis and quality of life.",{"@graph":14,"@context":65},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/advances-in-targeted-therapy-and-biomarker-research-in-thyroid-cancer/327154/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/advances-in-targeted-therapy-and-biomarker-research-in-thyroid-cancer/327154.png","ImageObject",300,407,{"name":42,"@type":43},"Lucas Martin","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-11-04","2026-09-21",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",9,{"@type":57,"mainEntity":58},"FAQPage",[59],{"name":60,"@type":61,"acceptedAnswer":62},"How do biomarkers help clinicians in thyroid cancer management?","Question",{"text":63,"@type":64},"Biomarkers support patient categorization based on molecular profiles, enabling customized therapy regimens and maximizing therapeutic results.","Answer","https://schema.org",{"og:url":32,"og:type":67,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":69,"canonical":32},"index,follow",{"doc_id":71,"site_id":7},327154,1790198750,{"code":4,"msg":74,"data":75},"success",[76,80,84,88,93,98,103,107,111,114,118],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":77,"show_sort_weight":78,"slug":79},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":81,"show_sort_weight":82,"slug":83},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Exam",70,"exam",{"id":89,"doc_module":4,"doc_module_name":25,"category_name":90,"show_sort_weight":91,"slug":92},5,"Comic",60,"comic",{"id":94,"doc_module":4,"doc_module_name":25,"category_name":95,"show_sort_weight":96,"slug":97},6,"Technology",50,"technology",{"id":99,"doc_module":4,"doc_module_name":25,"category_name":100,"show_sort_weight":101,"slug":102},7,"Healthcare",40,"healthcare",{"id":104,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":105,"slug":106},8,30,"research-report",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},"Religion & Spirituality",20,"religion-spirituality",{"id":109,"doc_module":4,"doc_module_name":25,"category_name":112,"show_sort_weight":109,"slug":113},"World Cup","world-cup",{"id":115,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":115,"slug":117},10,"Lifestyle","lifestyle",{"id":119,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":89,"slug":121},19,"General","general",{"code":4,"msg":74,"data":123},{"doc_id":71,"user_id":124,"nickname":42,"user_avatar":125,"doc_module":4,"category_id":104,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":126,"file_id":127,"file_url":128,"file_type":129,"file_size":130,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":131,"language":132,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":133,"faqs":134,"seo_title":135,"seo_description":12,"update_tm":136,"read_time":101,"preview_page_count":4},8796095360427,"https://ap-avatar.wpscdn.com/davatar_994ba38a5ba835b3df7d355c54d3ed8d","TYPE Review  \nPUBLISHED 04 March 2024  \nDOI 10.3389/fendo.2024.1372553  \nOPEN ACCESS  \nEDITED BY Min Tu,  \nNanjing Medical University, China  \nREVIEWED BY Feixiang Liu,  \nFirst Affiliated Hospital of Henan University of Traditional Chinese Medicine, China  \nPing Qiu,  \nZhejiang Chinese Medical University, China  \n*CORRESPONDENCE Mei Guo  \n [370110@njucm.edu.cn](370110@njucm.edu.cn)[ ](370110@njucm.edu.cn)Chun Zhang  \n [260316@njucm.edu.cn](260316@njucm.edu.cn)  \nRECEIVED 18 January 2024  \nACCEPTED 19 February 2024  \nPUBLISHED 04 March 2024  \nCITATION  \nGuo M, Sun Y, Wei Y, Xu J and Zhang C (2024) Advances in targeted therapy and biomarker research in thyroid cancer.  \nFront. Endocrinol. 15:1372553 .  \ndoi: 10.3389/fendo.2024.1372553  \nCOPYRIGHT  \n© 2024 Guo, Sun, Wei, Xu and Zhang. This isan open-access article distributed under the terms of the Creative Commons Attribution License (CC BY) . The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.  \nAdvances in targeted therapy and biomarker research in thyroid cancer  \nMei Guo 1*, Yuqi Sun 2, Yuyao Wei 2, Jianxin Xu 2 and Chun Zhang 3*  \n1School of Nursing, Nanjing University of Chinese Medicine, Nanjing, China, 2School of Pharmacy, Nanjing University of Chinese Medicine, Nanjing, China, 3Affiliated Hospital of Nanjing University of Chinese Medicine, Nanjing, China  \nDriven by the intricacy of the illness and the need for individualized treatments, targeted therapy and biomarker research in thyroid cancer represent an important frontier in oncology. The variety of genetic changes associated with thyroid cancer demand more investigation to elucidate molecular details. This research is clinically significant since it can be used to develop customized treatment plans. A more focused approach is provided by targeted therapies, which target certain molecular targets such as mutant BRAF or RET proteins. This strategy minimizes collateral harm to healthy tissues and may also reduce adverse effects. Simultaneously, patient categorization based on molecular profiles is made possible by biomarker exploration, which allows for customized therapy regimens and maximizes therapeutic results. The benefits of targeted therapy and biomarker research go beyond their immediate clinical impact to encompass the whole cancer landscape. Comprehending the genetic underpinnings of thyroid cancer facilitates the creation of novel treatments that specifically target aberrant molecules. This advances the treatment of thyroid cancer and advances precision medicine, paving the way for the treatment of other cancers. Taken simply, more study on thyroid cancer is promising for better patient care. The concepts discovered during this investigation have the potential to completely transform the way that care is provided, bringing in a new era of personalized, precision medicine . This paradigm shift could improve the prognosis and quality of life for individuals with thyroid cancer and act as an inspiration for advances in other cancer types.  \nKEYWORDS  \nthyroid cancer, targeted therapy, biomarker research, disease treatment, clinical application  \nFrontiers in Endocrinology 01 [frontiersin.org](frontiersin.org)  \n1 Introduction  \nThyroid cancer originates from the thyroid gland, a butterflyshaped organ located near the base of the neck (1) . There has been arise in its occurrence during the last several years (2) . Thyroid cancer risk factors include radiation exposure, particular genetic abnormalities, and a family history of the disease (3) . Women are more likely than men to develop thyroid cancer, and the risk increases with age (3) . Some regions with high iodine intake might have a higher prevalence of subtypes of thyroid cancer (4) ","cbCaiixosReNAABP","https://ap.wps.com/l/cbCaiixosReNAABP","pdf",943213,16,"English","# Introduction\n## Molecular biomarkers in thyroid cancer","[{\"question\":\"How do biomarkers help clinicians in thyroid cancer management?\",\"answer\":\"Biomarkers support patient categorization based on molecular profiles, enabling customized therapy regimens and maximizing therapeutic results.\"}]","Advances in targeted therapy and biomarker research in thyroid cancer | PDF",1789976557]